| Dr David G Miller, MD | |
|
3401 Enterprise Pkwy, Suite 300, Beachwood, OH 44122-7341 | |
| (216) 831-5700 | |
| (216) 831-1959 |
| Full Name | Dr David G Miller |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 31 Years |
| Location | 3401 Enterprise Pkwy, Beachwood, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992799191 | NPI | - | NPPES |
| 2059561 | Medicaid | OH | |
| 35-07-4140-M | Other | OH | OHIO LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | 35-074140 (Ohio) | Primary |
| 207W00000X | Ophthalmology | 35-07-4140-M (Ohio) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina Associates Of Cleveland, Inc. | 2769463785 | 15 |
News Archive
As part of its commitment to providing the highest quality of care to the community, Tower Hematology Oncology Medical Group has announced the formation of Tower Oncology's Cancer Support Network.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.
Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to findings from a clinical trial supported by the National Institutes of Health.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Entity Name | Retina Associates Of Cleveland, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912991225 PECOS PAC ID: 2769463785 Enrollment ID: O20040526000715 |
News Archive
As part of its commitment to providing the highest quality of care to the community, Tower Hematology Oncology Medical Group has announced the formation of Tower Oncology's Cancer Support Network.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.
Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to findings from a clinical trial supported by the National Institutes of Health.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Entity Name | Parschauer Eye Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083675961 PECOS PAC ID: 8921033929 Enrollment ID: O20050928000947 |
News Archive
As part of its commitment to providing the highest quality of care to the community, Tower Hematology Oncology Medical Group has announced the formation of Tower Oncology's Cancer Support Network.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.
Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to findings from a clinical trial supported by the National Institutes of Health.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David G Miller, MD 3401 Enterprise Pkwy, Suite 300, Beachwood, OH 44122-7341 Ph: (216) 831-5700 | Dr David G Miller, MD 3401 Enterprise Pkwy, Suite 300, Beachwood, OH 44122-7341 Ph: (216) 831-5700 |
News Archive
As part of its commitment to providing the highest quality of care to the community, Tower Hematology Oncology Medical Group has announced the formation of Tower Oncology's Cancer Support Network.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.
Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to findings from a clinical trial supported by the National Institutes of Health.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
Lisa Douglass Lystad, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 23250 Chagrin Blvd, Bld 5 Ste 440, Beachwood, OH 44122 Phone: 216-514-1864 Fax: 216-514-1867 | |
Dr. Shawn Ashwin Lewis, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 24075 Commerce Park, Beachwood, OH 44122 Phone: 216-831-5704 Fax: 216-831-1959 | |
David J Mitchell, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 24755 Chagrin Blvd, Suite 345, Beachwood, OH 44122 Phone: 216-297-3230 Fax: 216-342-5290 | |
Mrs. Kubra Sarici, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 26525 Amhearst Cir Apt 5-208, Beachwood, OH 44122 Phone: 216-387-7936 | |
Michael A Novak, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3401 Enterprise Pkwy, Suite 300, Beachwood, OH 44122 Phone: 216-831-5700 Fax: 216-839-4905 | |
Stephen Ross Bernie, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 24300 Chagrin Blvd, Suite 210, Beachwood, OH 44122 Phone: 216-454-0009 Fax: 216-991-5190 | |
Dr. Harrison Dean Sciulli, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 24075 Commerce Park, Beachwood, OH 44122 Phone: 216-831-5700 |